Last reviewed · How we verify
Lymphomatous meningitis
Approved treatments
- Cytarabine · Nippon Shinyaku Co., Ltd.
Cytarabine inhibits DNA polymerase and incorporates into DNA/RNA, killing cells in S-phase.
Clinical guidelines
- FDA label — any
Intrathecal administration of Cytarabine Injection is indicated in the prophylaxis and treatment. - FDA label — any
Intrathecal administration of Cytarabine Injection is indicated in the prophylaxis and treatment.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Lymphomatous meningitis patent landscape — cliff calendar, originator estates, attackable patents
- Lymphomatous meningitis treatment landscape brief
- Lymphomatous meningitis treatment updates RSS
Frequently asked questions about Lymphomatous meningitis
What drugs treat Lymphomatous meningitis?
Tracked treatments include Cytarabine.
What is the treatment for Lymphomatous meningitis?
Standard treatment for Lymphomatous meningitis includes Cytarabine. See the treatment landscape page for first-line, second-line and salvage options.
What are the treatment guidelines for Lymphomatous meningitis?
FDA label publishes guidelines for Lymphomatous meningitis. 2 guideline references tracked.
Related
- Treatment landscape: Lymphomatous meningitis patent cliff · Lymphomatous meningitis CI report
- Treatment: Cytarabine · Nippon Shinyaku Co., Ltd.
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing